News

Fungal Meningitis Outbreak Exposes Lack of Regulatory Oversight


 

The 23 states that received the implicated lots of medication are California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Maryland, Michigan, Minnesota, North Carolina, New Hampshire, New Jersey, Nevada, New York, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, and West Virginia.

All reports of complaints or problems associated with these products should be made at the MedWatch website, the FDA’s voluntary reporting program, or by calling 800-FDA-1088.

Pages

Recommended Reading

Inappropriate Medications for the Elderly: Three Big Offenders
MDedge Internal Medicine
Topical Pain Relievers: FDA Issues Burn Warning
MDedge Internal Medicine
Prescription Drug Abuse Declines, Marijuana Use Still Common
MDedge Internal Medicine
Depression can be migraine's tipping point
MDedge Internal Medicine
Chronic Musculoskeletal Pain Travels with Chronic Daily Headache
MDedge Internal Medicine
Yoga, Tai Chi Underused in Rheumatic Pain Management
MDedge Internal Medicine
Botox for Chronic Migraine Brings Cost Savings
MDedge Internal Medicine
Botox May Greatly Reduce Migraine Chronicity
MDedge Internal Medicine
Fungal Meningitis Cases, Deaths Continue to Rise
MDedge Internal Medicine
Weighing Botox's Migraine Benefits Against Costs
MDedge Internal Medicine